SecBot SecBot
8-K ·Filed Nov 5, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
BULLISH
Impact 6/10
Horizonmonths Processed11d 20h ago SEC0001104659-26-123030
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Revenue growth and margin expansion are accelerating, with FY26 guidance maintained. Key catalysts ahead include sBLA submission for lifileucel in mNSCLC in 2027 and potential UK/Switzerland approvals in 1Q27. Monitor enrollment updates in the SARATOGA and TILVANCE-301 registrational trials.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$7.74
T+0 close · Nov 5, 2026 · via day close
Latest settled
−1.42%
T+5 · $7.63
Vs SPY
−4.71%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $7.74entry
  2. T+1 · 11d ago +3.88%α +3.56% · $8.04
  3. T+5 · 5d ago −1.42%α −4.71% · $7.63
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin improving to ~60%. The company maintained its FY26 revenue guidance of $410M-$420M and highlighted positive clinical data in NSCLC and sarcoma. Cash position of ~$382M is expected to fund operations well into 2029.

Key Financial Metrics

Revenue
$121.5M
est $115.6M · +5.1% · +80.1% YoY
Guidance
$410M-$420M
maintained
Gross Margin
60%

Key Facts

  • Q3 2026 total product revenue of ~$122M, up ~80% from ~$67M in Q3 2025 and ~22% from ~$99M in Q2 2026
  • U.S. Amtagvi revenue of ~$102M, up ~77% YoY and ~12% sequentially
  • Gross margin of ~60%, up from 56% in Q2 2026
  • R&D expenses decreased ~16% sequentially, marking fifth straight quarter of improvement
  • FY26 revenue guidance maintained at $410M-$420M
  • Cash position of ~$382M as of September 30, 2026, expected to fund operations well into 2029
  • 24.6% ORR in 69 patients with non-squamous mNSCLC in IOV-LUN-202 trial; 59.1% ORR in biomarker-selected subgroup
  • 55.6% confirmed ORR in UPS and DDLPS in SARATOGA trial
  • Net loss narrowed to $22.3M from $91.3M in Q3 2025

Financial Impact

Record quarterly revenue of ~$122M, 80% YoY growth; gross margin expanded to ~60%; operating loss narrowed to ~$24M from ~$95M in Q3 2025

revenuegross marginoperating losscash position

Risk Factors

  • Company remains pre-profitability with net loss of $22.3M in Q3 2026
  • Dependence on continued Amtagvi commercial adoption and ATC network expansion
  • Clinical and regulatory risks for pipeline programs in NSCLC, sarcoma, and endometrial cancer
  • Potential dilution from equity financing needs if cash runway extends beyond current projections

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-123030
Document: tm2628901d1_8k.htm0001104659-26-123030
Document: 0001104659-26-123030-index-headers.html0001104659-26-123030
Document: 0001104659-26-123030-index.html0001104659-26-123030
Document: 0001104659-26-123030.txt0001104659-26-123030
8-K Data (Synthetic)0001104659-26-123030

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026